Ascendis Pharma ( (ASND) ) has provided an announcement.
On March 20, 2025, VISEN Pharmaceuticals announced the pricing of its initial public offering (IPO) on the Hong Kong Stock Exchange, with shares priced at HKD 68.80 each. The IPO is expected to generate gross proceeds of approximately USD 100 million, with a potential additional HKD 117,489,760 from a greenshoe option. Ascendis Pharma, a significant shareholder in VISEN, holds 41,136,364 shares and is subject to lock-up agreements restricting the sale of shares for up to 12 months post-IPO, ensuring continued control and stability in VISEN’s shareholder structure.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for unmet medical needs. The company is known for its TransCon technology platform, which aims to create best-in-class therapeutics across multiple therapeutic areas.
YTD Price Performance: 20.33%
Average Trading Volume: 464,005
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.85B
See more data about ASND stock on TipRanks’ Stock Analysis page.